CCLA Investment Management Boosts Stock Position in Zoetis Inc. $ZTS

CCLA Investment Management grew its stake in shares of Zoetis Inc. (NYSE:ZTS) by 14.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 959,604 shares of the company’s stock after acquiring an additional 124,390 shares during the period. Zoetis accounts for approximately 0.1% of CCLA Investment Management’s portfolio, making the stock its 17th largest holding. CCLA Investment Management owned 0.22% of Zoetis worth $149,583,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. GoalVest Advisory LLC raised its position in shares of Zoetis by 36.8% in the second quarter. GoalVest Advisory LLC now owns 602 shares of the company’s stock worth $94,000 after buying an additional 162 shares in the last quarter. Ashton Thomas Private Wealth LLC raised its position in shares of Zoetis by 6.5% in the second quarter. Ashton Thomas Private Wealth LLC now owns 27,544 shares of the company’s stock worth $4,295,000 after buying an additional 1,674 shares in the last quarter. Baer Investment Advisory LLC raised its position in shares of Zoetis by 39.1% in the second quarter. Baer Investment Advisory LLC now owns 18,021 shares of the company’s stock worth $3,053,000 after buying an additional 5,069 shares in the last quarter. Envestnet Asset Management Inc. raised its position in shares of Zoetis by 0.8% in the second quarter. Envestnet Asset Management Inc. now owns 2,189,242 shares of the company’s stock worth $341,412,000 after buying an additional 17,291 shares in the last quarter. Finally, Resonant Capital Advisors LLC raised its position in shares of Zoetis by 15.5% in the second quarter. Resonant Capital Advisors LLC now owns 2,382 shares of the company’s stock worth $371,000 after buying an additional 319 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a research report on Friday. Leerink Partnrs downgraded Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. UBS Group lowered their price target on Zoetis from $165.00 to $158.00 and set a “neutral” rating on the stock in a research report on Monday, October 20th. Argus restated a “buy” rating and set a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. Finally, Piper Sandler raised their price target on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Four analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, Zoetis currently has a consensus rating of “Hold” and an average target price of $195.00.

Zoetis Stock Down 0.2%

Shares of NYSE:ZTS opened at $146.14 on Monday. The stock’s 50-day moving average price is $148.18 and its 200-day moving average price is $153.57. Zoetis Inc. has a 12-month low of $139.34 and a 12-month high of $184.40. The stock has a market capitalization of $64.77 billion, a P/E ratio of 25.15, a price-to-earnings-growth ratio of 2.35 and a beta of 0.90. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.41 billion. During the same period last year, the firm earned $1.56 earnings per share. The company’s revenue for the quarter was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s dividend payout ratio (DPR) is 34.42%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.